{"title":"Use of Social Networks and Impact on Adolescents","authors":"Faton Kutllovci, Sylen Vranica, Niman Bardhi","doi":"10.14744/ejmi.2019.44556","DOIUrl":"https://doi.org/10.14744/ejmi.2019.44556","url":null,"abstract":"DOI: 10.14744/ejmi.2019.44556 EJMI 2020;4(1):36–40","PeriodicalId":310818,"journal":{"name":"Eurasian Journal of Medical Investigation","volume":"322 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124555502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.14744/ejmi.2022.72208
S. Ay
Objectives: Small cell lung cancer (SCLC) is approximately 15% of all lung cancer. Topotecan is the preferred chemotherapy regimen in second-line treatment, but toxicity might be limiting to use in clinical routine. Physicians had more experience on weekly paclitaxel due to its easy access and good responses in many cancers. The present study aimed to examine the management of patients treated with topotecan and weekly paclitaxel as second-line treatment of SCLC. Methods: Patients were divided into two groups due to second-line treatment. The primary endpoint of this study was progression-free survival and overall survival. The secondary endpoint was overall response rate and disease control rate. Results: The median PFS was 4.5 months (Topotecan 3.7 vs. Paclitaxel 5.5, HR = 0.34, 95% CI: 0.30-0.64, p=0.000) and the median OS was 11 months (Topotecan 9.5 vs. Paclitaxel 12.7, HR = 0.25, 95% CI: 0.20-0.45, p=0.000). ORR was 10.2 % in topotecan group and 20.3%% in paclitaxel group (p: 0.047). DCR was 15.5% in patients treated with topotecan and 28.8% in paclitaxel group (p=0.033). Conclusion: The present study compared the currently preferred regimen topotecan with weekly paclitaxel and resulted in better survival and response rates with lower toxicity profile. Abstract
{"title":"Second Line Treatment Choice in Extensive Small Lung Cancer","authors":"S. Ay","doi":"10.14744/ejmi.2022.72208","DOIUrl":"https://doi.org/10.14744/ejmi.2022.72208","url":null,"abstract":"Objectives: Small cell lung cancer (SCLC) is approximately 15% of all lung cancer. Topotecan is the preferred chemotherapy regimen in second-line treatment, but toxicity might be limiting to use in clinical routine. Physicians had more experience on weekly paclitaxel due to its easy access and good responses in many cancers. The present study aimed to examine the management of patients treated with topotecan and weekly paclitaxel as second-line treatment of SCLC. Methods: Patients were divided into two groups due to second-line treatment. The primary endpoint of this study was progression-free survival and overall survival. The secondary endpoint was overall response rate and disease control rate. Results: The median PFS was 4.5 months (Topotecan 3.7 vs. Paclitaxel 5.5, HR = 0.34, 95% CI: 0.30-0.64, p=0.000) and the median OS was 11 months (Topotecan 9.5 vs. Paclitaxel 12.7, HR = 0.25, 95% CI: 0.20-0.45, p=0.000). ORR was 10.2 % in topotecan group and 20.3%% in paclitaxel group (p: 0.047). DCR was 15.5% in patients treated with topotecan and 28.8% in paclitaxel group (p=0.033). Conclusion: The present study compared the currently preferred regimen topotecan with weekly paclitaxel and resulted in better survival and response rates with lower toxicity profile. Abstract","PeriodicalId":310818,"journal":{"name":"Eurasian Journal of Medical Investigation","volume":"76 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114858153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.14744/ejmi.2022.14970
F. Ferhatoğlu
Objectives: Sunitinib is the preferred second-line treatment option to imatinib escalation in patients with imatinib-resistant advanced gastrointestinal stromal tumors. In this study, we aimed to determine the risk factors affecting survival and sunitinib-related toxicities in imatinib-resistance GIST patients. Methods: Clinical characteristics of 40 imatinib-resistant GIST patients who received second-line sunitinib were evaluated. Statistical analysis was performed to determine risk factors associated with survival and sunitinib-related toxicities. Results: The median age was 53 and the male to female ratio was 24/16. The most common of the primary tumor location was small bowel (25; 62.5%). There were 17 (42.5%) patients who developed resistance to imatinib within the first 24 months. Median overall survival (OS) and progression-free survival were 31.6 months and 19.6 months, respectively. Among many risk factors, best response to sunitinib (Hazard ratio [HR]: 2.34) and imatinib resistance (HR: 0.43 were independent prognostics for OS. The only risk factor for sunitinib-related grade 3 or 4 toxicity was advanced age (Odds ratio: 1.90). Conclusion: Long-term use of imatinib and best response to sunitinib are the most important clinical parameters to evaluate the efficacy of sunitinib. Sunitinib-related toxicity is frequently observed and has a high potential for toxicity in elderly patients. Abstract Drug-Relat-
{"title":"Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib","authors":"F. Ferhatoğlu","doi":"10.14744/ejmi.2022.14970","DOIUrl":"https://doi.org/10.14744/ejmi.2022.14970","url":null,"abstract":"Objectives: Sunitinib is the preferred second-line treatment option to imatinib escalation in patients with imatinib-resistant advanced gastrointestinal stromal tumors. In this study, we aimed to determine the risk factors affecting survival and sunitinib-related toxicities in imatinib-resistance GIST patients. Methods: Clinical characteristics of 40 imatinib-resistant GIST patients who received second-line sunitinib were evaluated. Statistical analysis was performed to determine risk factors associated with survival and sunitinib-related toxicities. Results: The median age was 53 and the male to female ratio was 24/16. The most common of the primary tumor location was small bowel (25; 62.5%). There were 17 (42.5%) patients who developed resistance to imatinib within the first 24 months. Median overall survival (OS) and progression-free survival were 31.6 months and 19.6 months, respectively. Among many risk factors, best response to sunitinib (Hazard ratio [HR]: 2.34) and imatinib resistance (HR: 0.43 were independent prognostics for OS. The only risk factor for sunitinib-related grade 3 or 4 toxicity was advanced age (Odds ratio: 1.90). Conclusion: Long-term use of imatinib and best response to sunitinib are the most important clinical parameters to evaluate the efficacy of sunitinib. Sunitinib-related toxicity is frequently observed and has a high potential for toxicity in elderly patients. Abstract Drug-Relat-","PeriodicalId":310818,"journal":{"name":"Eurasian Journal of Medical Investigation","volume":"136 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116381727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.14744/ejmi.2022.42746
M. Aykan
Objectives: To aim to show the survival outcomes of ifosfamide, carboplatin and etoposide (ICE) therapy and the characteristics of treatment-related hematological side effects in patients with relapsed/refractory bone sarcomas (BSs) and soft tissue sarcomas (STSs). Methods: Patients who were treated at the Department of Medical Oncology, Gulhane School of Medicine between January 2017 and June 2021 were included. Post-ICE progression-free survival (PFS), overall survival (OS) rates and treatment-related hematological side effects were determined. Results: Fifty-six adult patients were included (thirty-four of them BSs). PFS was determined as 6.7 ± 4.4 months and 7.1±3.6 months for STSs and BSs, respectively. OS was 11.4±5.6 monhts and 12.6±7.1 for STSs and BSs, respectively. PFS and OS were not found to be better between groups (p=0.84 and p=0.517, respectively). The median OS and PFS after ICE protocol in patients with two or less systemic chemotherapy lines were significantly higher than those who received three or more lines (7.85±1.66 vs 3.74 ±2.89, p=0.001 and 13.80±8.45 vs 6.73, p=0.001). Conclusion: In addition to its contribution for all patients, ICE may contribute to longer survival, especially in patients receiving ≤2 lines of systemic chemotherapy. Abstract Article: Aykan Efficacy of Ifosfamide, Carboplatin Etoposide Protocol the Relapsed
目的:旨在显示异磷酰胺、卡铂和依托泊苷(ICE)治疗复发/难治性骨肉瘤(BSs)和软组织肉瘤(STSs)患者的生存结局和治疗相关血液学副作用的特点。方法:纳入2017年1月至2021年6月在Gulhane医学院肿瘤内科治疗的患者。确定ice后无进展生存期(PFS)、总生存期(OS)和治疗相关的血液学副作用。结果:纳入56例成人患者，其中34例为BSs。STSs和BSs的PFS分别为6.7±4.4个月和7.1±3.6个月。STSs和BSs的OS分别为11.4±5.6个月和12.6±7.1个月。PFS和OS组间差异无统计学意义(p=0.84, p=0.517)。接受2种或更少系统化疗方案的患者，ICE方案后的中位OS和PFS显著高于接受3种或更多系统化疗方案的患者(7.85±1.66 vs 3.74±2.89,p=0.001和13.80±8.45 vs 6.73, p=0.001)。结论:除了对所有患者的贡献外，ICE可能有助于延长生存期，特别是接受≤2线全身化疗的患者。摘要文章:艾坎对异环磷酰胺、卡铂依托泊苷治疗复发的疗效
{"title":"Efficacy of Ifosfamide, Carboplatin and Etoposide Protocol in the Treatment of Relapsed or Refractory Bone and Soft Tissue Sarcomas","authors":"M. Aykan","doi":"10.14744/ejmi.2022.42746","DOIUrl":"https://doi.org/10.14744/ejmi.2022.42746","url":null,"abstract":"Objectives: To aim to show the survival outcomes of ifosfamide, carboplatin and etoposide (ICE) therapy and the characteristics of treatment-related hematological side effects in patients with relapsed/refractory bone sarcomas (BSs) and soft tissue sarcomas (STSs). Methods: Patients who were treated at the Department of Medical Oncology, Gulhane School of Medicine between January 2017 and June 2021 were included. Post-ICE progression-free survival (PFS), overall survival (OS) rates and treatment-related hematological side effects were determined. Results: Fifty-six adult patients were included (thirty-four of them BSs). PFS was determined as 6.7 ± 4.4 months and 7.1±3.6 months for STSs and BSs, respectively. OS was 11.4±5.6 monhts and 12.6±7.1 for STSs and BSs, respectively. PFS and OS were not found to be better between groups (p=0.84 and p=0.517, respectively). The median OS and PFS after ICE protocol in patients with two or less systemic chemotherapy lines were significantly higher than those who received three or more lines (7.85±1.66 vs 3.74 ±2.89, p=0.001 and 13.80±8.45 vs 6.73, p=0.001). Conclusion: In addition to its contribution for all patients, ICE may contribute to longer survival, especially in patients receiving ≤2 lines of systemic chemotherapy. Abstract Article: Aykan Efficacy of Ifosfamide, Carboplatin Etoposide Protocol the Relapsed","PeriodicalId":310818,"journal":{"name":"Eurasian Journal of Medical Investigation","volume":"8 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116485657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.14744/ejmi.2022.16843
Deniz Tataroglu Ozyukseler
in-Objectives: Although pancreatic cancer is comparatively rare, it's
目的:虽然胰腺癌相对罕见，但它是一种恶性肿瘤
{"title":"The Systemic Inflammation Response Index as a Prognostic Marker in Advanced Pancreatic Cancer","authors":"Deniz Tataroglu Ozyukseler","doi":"10.14744/ejmi.2022.16843","DOIUrl":"https://doi.org/10.14744/ejmi.2022.16843","url":null,"abstract":"in-Objectives: Although pancreatic cancer is comparatively rare, it's","PeriodicalId":310818,"journal":{"name":"Eurasian Journal of Medical Investigation","volume":"94 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124693270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.14744/ejmi.2022.11286
B. Ozkul
{"title":"The Role of Simultaneous Standardized Uptake Value and MRI Diffusion Weighted Heterogeneity Index from Hybrid PET/MR in the Evaluation of Brain Metastases","authors":"B. Ozkul","doi":"10.14744/ejmi.2022.11286","DOIUrl":"https://doi.org/10.14744/ejmi.2022.11286","url":null,"abstract":"","PeriodicalId":310818,"journal":{"name":"Eurasian Journal of Medical Investigation","volume":"6 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125073236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.14744/EJMI.2019.14976
Edhem Unver, A. Çikman, F. Karakeçili, A. Koç, U. Binay, E. Karavaş
{"title":"Microorganisms Causing Ventilator-Associated Pneumonia And Their Antibiotic Susceptibility","authors":"Edhem Unver, A. Çikman, F. Karakeçili, A. Koç, U. Binay, E. Karavaş","doi":"10.14744/EJMI.2019.14976","DOIUrl":"https://doi.org/10.14744/EJMI.2019.14976","url":null,"abstract":"","PeriodicalId":310818,"journal":{"name":"Eurasian Journal of Medical Investigation","volume":"77 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128586636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Response Rates and Predictive Factors of Pathological Complete Response to Neoadjuvant Chemotherapy in Luminal B HER2 Negative Breast Cancer","authors":"Nilay Sengul Samanci","doi":"10.14744/ejmi.2021.13576","DOIUrl":"https://doi.org/10.14744/ejmi.2021.13576","url":null,"abstract":"DOI: 10.14744/ejmi.2021.13576 EJMI 2021;5(4):476–480","PeriodicalId":310818,"journal":{"name":"Eurasian Journal of Medical Investigation","volume":"6 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129296285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Impact of Iron Deficiency Anemia on Health Related Quality of Life in the Last Trimester of Pregnancy","authors":"E. Yılmaz, Ç. Soysal, B. Icer, Z. Yılmaz, S. Özkan, T. Küçüközkan","doi":"10.14744/EJMI.2019.65035","DOIUrl":"https://doi.org/10.14744/EJMI.2019.65035","url":null,"abstract":"DOI: 10.14744/ejmi.2019.65035 EJMI 2019;3(3):182–188","PeriodicalId":310818,"journal":{"name":"Eurasian Journal of Medical Investigation","volume":"44 8","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133008118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.14744/ejmi.2022.66533
O. Sever
Objectives: The aim of our study is to determine the relationship between clinicopathological parameters and survival in our patients with testicular cancer who were followed up and treated in our centers. Methods: Patients who were followed up and treated with the diagnosis of testicular cancer in Antalya Training and Research Hospital and Sanko University Hospital Medical Oncology Clinics were evaluated retrospectively. Results: 164 patients with a mean age of 32.8±10.8 (range 15.6-67) years were included in the study. Seminoma was detected in 68 (41.5%) patients, non-seminomatous germ cell tumor (NSGCT) was detected in 91 (55.5%) patients, and non-germ cell testicular carcinoma was detected in 5 (3%) patients. A statistically significant difference was found between histological type and age (p<0.001). Mean age was 37.4±10.1 (range 20-67) years in seminoma patients, 28.4±8.6 (range 15.6-52.14) years in NSGCT patients, 53.6±9.6 (range 41.2-62.8) years in non-germ cell testicular cancers. A statistically significant difference was found between histological subtype and stage (p=0.003). Of the patients diagnosed with seminoma, 54 (85.7%) patients were stage I, 6 (9.5%) patients were stage II, and 3 (4.8%) patients were stage III. In the NSGCT group, 47 (54.7%) patients were stage I, 17 (19.8%) patients were stage II, 22 (25.6%) patients were stage III. Stage I disease was detected in all patients diagnosed with non-germ cell testicular tumor. Conclusion: Testicular cancer is the most common solid tumor seen in men aged 20-34 years. NSGCTs are diagnosed at a more advanced stage compared to seminomas. Abstract
{"title":"Survival Analysis of Our Patients Diagnosed with Testicular Cancer","authors":"O. Sever","doi":"10.14744/ejmi.2022.66533","DOIUrl":"https://doi.org/10.14744/ejmi.2022.66533","url":null,"abstract":"Objectives: The aim of our study is to determine the relationship between clinicopathological parameters and survival in our patients with testicular cancer who were followed up and treated in our centers. Methods: Patients who were followed up and treated with the diagnosis of testicular cancer in Antalya Training and Research Hospital and Sanko University Hospital Medical Oncology Clinics were evaluated retrospectively. Results: 164 patients with a mean age of 32.8±10.8 (range 15.6-67) years were included in the study. Seminoma was detected in 68 (41.5%) patients, non-seminomatous germ cell tumor (NSGCT) was detected in 91 (55.5%) patients, and non-germ cell testicular carcinoma was detected in 5 (3%) patients. A statistically significant difference was found between histological type and age (p<0.001). Mean age was 37.4±10.1 (range 20-67) years in seminoma patients, 28.4±8.6 (range 15.6-52.14) years in NSGCT patients, 53.6±9.6 (range 41.2-62.8) years in non-germ cell testicular cancers. A statistically significant difference was found between histological subtype and stage (p=0.003). Of the patients diagnosed with seminoma, 54 (85.7%) patients were stage I, 6 (9.5%) patients were stage II, and 3 (4.8%) patients were stage III. In the NSGCT group, 47 (54.7%) patients were stage I, 17 (19.8%) patients were stage II, 22 (25.6%) patients were stage III. Stage I disease was detected in all patients diagnosed with non-germ cell testicular tumor. Conclusion: Testicular cancer is the most common solid tumor seen in men aged 20-34 years. NSGCTs are diagnosed at a more advanced stage compared to seminomas. Abstract","PeriodicalId":310818,"journal":{"name":"Eurasian Journal of Medical Investigation","volume":"52 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131980434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：